Poseida Therapeutics (NASDAQ:PSTX) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

Poseida Therapeutics Trading Up 2.9 %

Shares of NASDAQ:PSTX opened at $2.87 on Thursday. Poseida Therapeutics has a one year low of $1.54 and a one year high of $4.27. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.18 and a quick ratio of 3.18. The firm has a 50 day simple moving average of $2.96 and a 200 day simple moving average of $2.95.

Poseida Therapeutics (NASDAQ:PSTX) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.09. Poseida Therapeutics had a negative return on equity of 94.90% and a negative net margin of 190.76%. The company had revenue of $25.00 million during the quarter, compared to analysts’ expectations of $12.50 million. As a group, research analysts anticipate that Poseida Therapeutics will post -1.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its holdings in Poseida Therapeutics by 110.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company’s stock worth $36,000 after acquiring an additional 5,606 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Poseida Therapeutics in the fourth quarter valued at $36,000. Allspring Global Investments Holdings LLC bought a new position in Poseida Therapeutics during the 3rd quarter worth $29,000. Barclays PLC raised its position in Poseida Therapeutics by 40.7% during the 3rd quarter. Barclays PLC now owns 45,542 shares of the company’s stock worth $109,000 after purchasing an additional 13,174 shares during the last quarter. Finally, Keystone Financial Group acquired a new position in Poseida Therapeutics during the 3rd quarter worth about $36,000. Institutional investors and hedge funds own 46.87% of the company’s stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.